From an April 23 article in the Economist magazine, which is on record advocating the legalization of all drugs, up to and including heroin, we learn how pleased the British are that President Donald Trump has fast-tracked approval of quick studies and FDA approval of ibogaine and other psychedelic drugs “for treating opioid addiction” and other matters.
“It is a watershed moment for a field that has struggled for years. From the 1940s to the 1960s work on psychedelics as medicines flourished. Tens of thousands of people used them as adjuncts to psychotherapy, with promising signs in alcoholism, addiction, PTSD and mood disorders. But the field floundered amid the moral panic over the 1960s counterculture and stricter rules on research and use that made further study difficult… Mr. Trump’s decision, then, is welcome news for the millions of people suffering with conditions that might be eased by psychedelic medicines.”
